OnCore Biopharma Announces Confidential Submission of Draft Registration Statement for Initial Public Offering DOYLESTOWN, Pa., Nov. 24, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. announced today that it has confidentially submitted a draft registration statement to the U.S. Securities and Exchange...

OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral...

OnCore Biopharma Agrees to Acquire Enantigen Therapeutics DOYLESTOWN, Pa., Oct. 1, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biotechnology company focused on the research, development and commercialization of oral...

OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection OnCore Secures Exclusive Worldwide Rights to NVP018 NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...

OnCore Biopharma Closes Series R Financing Funds to Expand OnCore's Portfolio of Oral Therapeutics for the Treatment of Chronic HBV OnCore to Advance HBV Compounds Into Phase 1 Clinical Development During 2015 Former Pharmasset Team...